IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Gene Therapy for Tay-Sachs Disease
This study has been completed.
Sponsor:
University of Minnesota - Clinical and Translational Science Institute
Collaborators:
Rare Diseases Clinical Research Network
National Center for Advancing Translational Science (NCATS)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier:
NCT01869270
First received: May 22, 2013
Last updated: December 3, 2014
Last verified: December 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Hypothesis: To study the natural history of Tay-Sachs disease and evaluate therapeutic interventions.
This study is intended to work in collaboration with NCT00668187 "A Natural History Study of Hexosaminidase Deficiency." Because so few patients with Tay-Sachs disease present annually, we will maximize both research projects by enrolling patients in both studies. For this present study, we will perform retrospective medical record review to gather data. Through this medical record review, we will collect biomarker analysis results, neuroimaging report data, quality-of-life questionnaire data and ophthalmology exam findings. If the subject has undergone therapy or treatment, the results will be noted.
| Condition |
|---|
| Tay Sachs Disease Sandhoff Disease Late Onset Tay Sachs Disease |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
| Official Title: | Gene Therapy for Tay-Sachs Disease (Phase 1: Natural History Data Gather) |
Resource links provided by NLM:
Genetic and Rare Diseases Information Center resources:
Gangliosidosis
Tay-Sachs Disease
Sandhoff Disease
Sphingolipidosis
U.S. FDA Resources
Further study details as provided by University of Minnesota - Clinical and Translational Science Institute:
Primary Outcome Measures:
- Biomarkers [ Time Frame: Participants will be followed for the duration of the study, an expected average of two years. ]
Biomarkers data to be collected include:
- CSF (cerebro-spinal fluid) hexosaminidase A activity
- CSF GM2-ganglioside
- CSF protein
- CSF chitotriosidase
Secondary Outcome Measures:
- Results of Ancillary Therapies or Treatments [ Time Frame: Participants will be followed for the duration of the study, an expected average of two years. ]The results of any ancillary therapies or treatments will be noted. Such therapies or treatments may include hematopoietic cell transplantation and/or pharmacologic interventions.
- Clinical Indicators [ Time Frame: Participants will be followed for the duration of the study, an expected average of two years. ]
Clinical indicators data to be collected include:
- Cranial morphology from MRI exam reports
- Ophthalmologic exam findings
- Behavioral assessment and quality-of-life questionnaire responses from NCT00668187, which collaborates with the present study
- Life-span length
| Enrollment: | 4 |
| Study Start Date: | December 2010 |
| Study Completion Date: | August 2014 |
| Primary Completion Date: | July 2014 (Final data collection date for primary outcome measure) |
Much has been done in the past four decades to better understand, improve diagnostic measures of, and prevent hexosaminidase deficiency diseases, yet all of them — Tay-Sachs, Sandhoff, and Late Onset Tay-Sachs (LOTS) — remain diseases without treatment. Much work remains to be done to understand and effectively treat these diseases. To date, no comprehensive assessment of the natural history of Tay-Sachs or Sandhoff has been undertaken. The information that is gathered through this study will characterize and describe the Tay-Sachs disease population as a whole, including the variability and progression of this disease. This information, in turn, will function as a point of reference against which to assess the efficacy of therapeutic interventions. Therapeutic interventions may include any treatments/therapies the subject may have undergone in the past, including hematopoietic cell transplantation, and/or the administration of miglustat, acetylcysteine, or other pharmaceutical agents; and possible future gene therapies.
Eligibility| Ages Eligible for Study: | Child, Adult, Senior |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Any person, living or dead, who has been diagnosed with a hexosaminidase deficiency disease
Criteria
Inclusion Criteria:
Any person who has been diagnosed with a hexosaminidase deficiency disease can be included in this study.
Exclusion Criteria:
The only exclusion criteria is a desire not to participate in this study.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01869270
Please refer to this study by its ClinicalTrials.gov identifier: NCT01869270
Locations
| United States, Florida | |
| Data Management and Coordinating Center (DMCC), Univ. of South Florida | |
| Tampa, Florida, United States, 33612 | |
| United States, Minnesota | |
| University of Minnesota | |
| Minneapolis, Minnesota, United States, 55455 | |
Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
Rare Diseases Clinical Research Network
National Center for Advancing Translational Science (NCATS)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
| Principal Investigator: | Chester B. Whitley, PhD, MD | University of Minnesota - Clinical and Translational Science Institute |
| Principal Investigator: | Jeffrey Krischer, PhD | University of South Florida |
More Information
Additional Information:
| Responsible Party: | University of Minnesota - Clinical and Translational Science Institute |
| ClinicalTrials.gov Identifier: | NCT01869270 History of Changes |
| Other Study ID Numbers: |
0905M66723 U54NS065768 ( U.S. NIH Grant/Contract ) |
| Study First Received: | May 22, 2013 |
| Last Updated: | December 3, 2014 |
Keywords provided by University of Minnesota - Clinical and Translational Science Institute:
|
Tay-Sachs disease Sandhoff disease late-onset Tay-Sachs disease adult-onset Tay-Sachs disease late onset Tay Sachs disease adult onset Tay Sachs disease hexosaminidase deficiency |
retrospective hexosaminidase A activity GM2-ganglioside gangliosidoses natural history hexosaminidase |
Additional relevant MeSH terms:
|
Tay-Sachs Disease Sandhoff Disease Lysosomal Storage Diseases, Nervous System Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases Nervous System Diseases Genetic Diseases, Inborn |
Lysosomal Storage Diseases Metabolic Diseases Lipid Metabolism Disorders Gangliosidoses, GM2 Gangliosidoses Sphingolipidoses Metabolism, Inborn Errors Lipidoses Lipid Metabolism, Inborn Errors |
ClinicalTrials.gov processed this record on July 21, 2017